CutCancer
Twinning for excellence to strategically advance research
in carcinogenesis and cancer.
Project objectives
In 2020, 2.7 million people in the European Union were diagnosed with cancer, and another 1.3 million people lost their lives to it, including over 2,000 young people.
The number of cancer cases in Europe is increasing each year, regardless of age, gender or social status, placing an enormous burden on health systems, patients, families and society in general.
As carcinogenesis is extremely heterogeneous, dynamic and complex system, holistic approaches that can analyse complex cellular and molecular interactions during cancer initiation and progression are crucial for the establishment of the basis for new prevention strategies and personalized anticancer treatments.
Recent advances in novel in vitro 3D test systems and utilizing novel state-of-the-art methodologies, enable the generation of more reliable and predictive in vitro data on cancer initation.
There is a failure in translating promising drug candidates and therapeutic approaches from the bench to the bedside that can also be attributed to the inadequate use of model systems in cancer research.
Applications towards designing in vitro, ex vivo and in vivo systems to reproduce cancer complexity and patient-specific tumours are increasingly investigated. Novel techniques in single-cell proteomics and spatial transcriptomics that enable visualization of cellular and molecular composition of tumours allow us to develop new personalized treatments for cancer patients.
Through twinning with excellent partners from UK (Swansea University; SWAN, Sweden (Stockholm University; SU) and the Netherlands (VU medical center Amsterdam; VUMC)
in the Cutcancer project, combined with ongoing substantial NIB infrastructural advances and significant research equipment upgrades, NIB will improve research knowledge and methodology in cancer research and foster field networking.
Recent News and Events
Discover most recent news and events.
Biological interaction at nanoscale
The National Institute of Biology (NIB) was proud to host researcher Dr. Marta Sendra Vega from the Department of Biotechnology and Food Sciences at the University…
NIB hands on training at SU
In October, our PhD student Simona Katrin Galun from the Department of genetic toxicology and cancer biology at the National institute of biology (NIB) visited Science…
In vitro hepatic 3D cell models and their application in genetic toxicology: a systematic review
Martina Štampar a, Bojana Žegura a a National Institute of Biology, Department of Genetic Toxicology and Cancer Biology, 1000 Ljubljana, Slovenia Read more
IMC workshop
The novel technology of Imaging Mass Cytometry (IMC) enables detailed and contextual characterisation of protein expression. IMC is a mass spectrometry-based technique that allows for the…
The 7th Congress titled “Challenges and traps of Tobacco Smoking and Related Products”
The Slovenian Toxicological Society organized the 7th Congress titled “Challenges and traps of Tobacco Smoking and Related Products“, held at the National Institute of Biology in…
Kemomind Science Conference 2024
The Kemomind Science Conference brings together the brightest minds in biomedical and analytical sciences for a transformative experience. With a focus on cutting-edge technology and interdisciplinary…
BEST days of science: AI and advanced technologies in science, interdisciplinary professional-educational event
BEST days of science: AI and advanced technologies in science, interdisciplinary professional-educational event (https://www.best-dnevi-znanosti.si/ ), was organized by students of the Faculty of Chemistry and Chemical…
NIB short visit to SciLifeLab, SU
Cancer Biology unit from NIB has visited SciLifeLab, prof. Mats Nilsson group from SU. In tha last year we have worked together on WP4; Uncovering changes…
Partners
Discover our partners, which helps us fight cancer.